| Identification | Back Directory | [Name]
2-Propenamide, N-[5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[methyl[2-(methylamino)ethyl]amino]-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]-, compd. with methanesulfonate (1:1) | [CAS]
2412155-75-8 | [Synonyms]
AST5902 mesylate
AST5902 mesylate(2412155-74-7 free base), 10 mM in DMSO
2-Propenamide, N-[5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[methyl[2-(methylamino)ethyl]amino]-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]-, compd. with methanesulfonate (1:1) | [Molecular Formula]
C27H29F3N8O2.CH4O3S | [MOL File]
2412155-75-8.mol | [Molecular Weight]
650.67 |
| Hazard Information | Back Directory | [Uses]
AST5902 mesylate is a principal metabolite of Alflutinib, exhibiting significant antineoplastic activity. AST5902 mesylate contributes to the overall pharmacological effects in the treatment of non-small cell lung cancer. AST5902 mesylate is involved in the response to activating EGFR mutations and can help overcome EGFR T790M drug-resistant mutations. | [References]
[1] Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers DOI:10.1007/s10637-021-01071-z |
|
|